Results 231 to 240 of about 83,207 (290)

Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar's Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9. [PDF]

World J Urol
Bahl A, Chilelli A, Faria R, Rozario N, Snijder R, Stark S, Merseburger AS.   +6 more
europepmc   +1 more source

Utility of Cytochemical and Flow Cytometry Detection of Alkaline Phosphatase for Differential Diagnosis of CD34+ Acute Leukaemia in Canines

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Alkaline phosphatase (ALP) enzymatic activity has been proposed as a marker for distinguishing canine acute leukaemia (AL) subtypes (i.e., myeloid vs. lymphoid). However, ALP enzymatic activity has not been fully evaluated in CD34+ AL. Determine whether ALP enzymatic activity can differentiate CD34+ AL subtypes in dogs and distinguish CD34+ AL
Megan Aalto, Janna Yoshimoto, Jillian Nolan, Kenzie Olsen, Dylan Ammons, Emily Rout, Anne C. Avery, R. Adam Harris   +7 more
wiley   +1 more source

Embedding genetic testing in the metastatic prostate cancer pathway: understanding patient and physician perspectives. [PDF]

Future Oncol
Jain R, Ribbands A, Butcher J, Barlow S, Skilling J, Stevens A, Pascoe K.   +6 more
europepmc   +1 more source

Phase 1 Dose Escalation of Single‐Agent Mechlorethamine in Dogs With Lymphoma

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Mechlorethamine is commonly prescribed to dogs at 3 mg/m2. The minimal toxicity observed indicates that higher doses of mechlorethamine are likely tolerable. The primary objective of this study was to determine the maximally tolerated dose (MTD) of mechlorethamine in dogs with lymphoma.
Laura E. Chadsey, Paul R. Hess, Joanne L. Intile   +2 more
wiley   +1 more source

Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study. [PDF]

Int J Urol
Suzuki K, Khan N, Taguchi T, Hattori K, Chen G, Ghadessi M, Constantinovici N, Quintero V, Suzuki H.   +8 more
europepmc   +1 more source

Outcome and Toxicity Profile of Stereotactic Body Radiation Therapy for Adrenal Tumours in Dogs

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Stereotactic body radiation therapy (SBRT) has become a non‐invasive alternative option for canine adrenal tumours with high surgical risks; however, its clinical benefits and risks are still to be fully understood. The goal of this multi‐institutional retrospective study was to describe the clinical outcome and safety of SBRT for the ...
Lily Thorsen, Kimberley Law, Jillian Walz, Valerie Morales Coll, Ada Naramor, Charles Maitz, Lyndsay Kubicek, Zebulon Thorsen, Jishnu Rao Gutti, Marilia Takada   +9 more
wiley   +1 more source

Apalutamide-induced rash and relative dose intensity in metastatic castration-sensitive prostate cancer: a multicenter Japanese cohort study. [PDF]

Transl Androl Urol
Urabe F, Onuma H, Tashiro K, Takahashi H, Uchida N, Kagawa H, Fujiwara K, Nakano J, Koike Y, Ohtsuka T, Hara S, Miyajima K, Ishikawa M, Fukuokaya W, Imai Y, Iwatani K, Atsuta M, Yanagisawa T, Murakami M, Yamamoto T, Miki J, Katsuta M, Kimura T.   +22 more
europepmc   +1 more source

Fluorine‐18 Fluorodeoxyglucose‐Positron Emission Tomography/Computed Tomography for Detection of Lymph Node Metastasis in Canine Mast Cell Tumour

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Lymph node (LN) metastasis has been associated with shorter survival times in dogs with mast cell tumour (MCT), and treatment of metastatic LN with lymphadenectomy or irradiation has been demonstrated to improve outcomes. Identification of metastatic LN in dogs with MCT is therefore of both prognostic and therapeutic significance.
Alison C. Williams, Monique N. Mayer, Ryan M. Dickinson, Sally L. Sukut, Valerie S. MacDonald‐Dickinson, Jerome Gagnon   +5 more
wiley   +1 more source

Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer. [PDF]

Neoplasia
Ahmad F, White M, Yamamoto K, Crooks DR, Agarwal S, Yang Y, Capaldo B, Raj S, Alilin AN, Ton A, Adler S, Seidel J, Olkowski C, Cherukuri MK, Choyke PL, Kelly K, Brender JR.   +16 more
europepmc   +1 more source

Disintegrin‐Like and Metalloprotease With Thrombospondin Type 1 Repeat Motifs 13 (ADAMTS13) Activity in 40 Healthy Dogs

Veterinary Clinical Pathology, EarlyView.
ABSTRACT Background In humans, deficiency of a disintegrin‐like and metalloprotease with thrombospondin type 1 motifs, number 13 (ADAMTS13), a von Willebrand factor (vWF) cleaving protease, is an underlying mechanism for thrombosis. The role of ADAMTS13 in canine thromboembolic disease is largely unknown.
Ashley R. Wilkinson, Priscila Beatriz da Silva Serpa, S. Michelle Todd   +2 more
wiley   +1 more source